With All Due Respect President Trump, Drug Companies Don't Want a Deregulated FDA
When President Donald Trump met with big pharma CEOs at the White House last month, he offered a combination of demands and olive branches. But the biopharma industry isn't particularly thrilled over one of his proposed gifts: a deregulated Food and Drug Administration (FDA) that speeds drug approvals past the regulatory finish line.
You'd think that the sector would champ at the bit for a stripped down FDA. But a first-to-market advantage doesn't mean much if there's not enough of a market to capitalize on. And that's exactly what's raising concerns among a number of prominent drug company executives who fear that insurance companies would be loathe to cover an unproven treatment.
You'd think that the sector would champ at the bit for a stripped down FDA. But a first-to-market advantage doesn't mean much if there's not enough of a market to capitalize on. And that's exactly what's raising concerns among a number of prominent drug company executives who fear that insurance companies would be loathe to cover an unproven treatment.